PharVision Advisers’s Texas Instruments TXN Stock Holding History

PharVision Advisers’s Portfolio TXN Stock Details TXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,878	Closed	-$345K	–	1016
2025 Q3	$345K	Buy	1,878 +675	+56%	+$132K	0.19%	145
2025 Q2	$250K	Buy	+1,203	New	+$214K	0.36%	137

Other funds holding TXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PharVision Advisers's TXN Position: Q4 2025 in Review

PharVision Advisers sold out of Texas Instruments (TXN) in Q4 2025, closing a stake of 1,878 shares — an estimated $345K sold.

PharVision Advisers first reported a position in TXN in Q2 2025 and held it in 2 quarters. The position peaked at $345K in Q3 2025. 2,396 funds tracked by Wall St. Rank hold TXN as of Q4 2025.

PharVision Advisers reported no remaining Texas Instruments position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,878 Texas Instruments shares in Q4 2025, an estimated $345K.
PharVision Advisers first reported a position in Texas Instruments in Q2 2025 and held it in 2 quarters.
PharVision Advisers's Texas Instruments position peaked at $345K in Q3 2025.
2,396 funds tracked by Wall St. Rank held Texas Instruments as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.